Zafgen Announces Transition of Board of Directors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St eyes best day in a month as Anthropic's IPO filing propels AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazilās Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Britain will not join Canada-led defence bank initiativeĀ
- CAE agrees to sell Flightscape unit to SITA for $500 million
FBR Capital Remains Bullish on Zafgen (ZFGN) Following Announced Orphan Designation of Beloranib in EU
September 30, 2015 10:31 AM EDTFBR Capital reiterated an Outperform rating on Zafgen (NASDAQ: ZFGN) following announced orphan designation of beloranib in the EU for the treatment of craniopharyngioma.
Analyst Christopher James commented, "This morning, Zafgen announced that it was granted orphan designation of beloranib in the EU for... More



